Munich Reinsurance Co Stock Corp in Munich Takes $2.78 Million Position in Bristol Myers Squibb Company $BMY

Munich Reinsurance Co Stock Corp in Munich purchased a new stake in Bristol Myers Squibb Company (NYSE:BMY) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 61,721 shares of the biopharmaceutical company’s stock, valued at approximately $2,784,000.

A number of other large investors also recently bought and sold shares of the business. Gateway Investment Advisers LLC raised its stake in Bristol Myers Squibb by 10.0% in the 3rd quarter. Gateway Investment Advisers LLC now owns 113,457 shares of the biopharmaceutical company’s stock valued at $5,117,000 after purchasing an additional 10,284 shares during the last quarter. CWA Asset Management Group LLC boosted its stake in Bristol Myers Squibb by 25.9% during the 3rd quarter. CWA Asset Management Group LLC now owns 150,359 shares of the biopharmaceutical company’s stock worth $6,781,000 after purchasing an additional 30,909 shares during the last quarter. Stephens Inc. AR boosted its stake in Bristol Myers Squibb by 13.5% during the 3rd quarter. Stephens Inc. AR now owns 273,343 shares of the biopharmaceutical company’s stock worth $12,328,000 after purchasing an additional 32,476 shares during the last quarter. Railway Pension Investments Ltd grew its holdings in shares of Bristol Myers Squibb by 3.7% during the third quarter. Railway Pension Investments Ltd now owns 1,139,600 shares of the biopharmaceutical company’s stock worth $51,396,000 after buying an additional 40,300 shares in the last quarter. Finally, Norges Bank acquired a new stake in shares of Bristol Myers Squibb in the second quarter valued at about $1,554,154,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. HSBC restated a “hold” rating and set a $53.00 price target on shares of Bristol Myers Squibb in a research report on Wednesday, December 10th. Morgan Stanley reiterated an “underweight” rating and issued a $40.00 price objective on shares of Bristol Myers Squibb in a report on Friday, February 6th. Truist Financial set a $65.00 target price on shares of Bristol Myers Squibb in a research note on Wednesday, December 3rd. Leerink Partners upped their price target on Bristol Myers Squibb from $54.00 to $60.00 and gave the company an “outperform” rating in a research report on Tuesday, January 13th. Finally, Citigroup increased their price target on Bristol Myers Squibb from $60.00 to $64.00 and gave the company a “neutral” rating in a report on Friday, February 6th. Nine investment analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $61.00.

Bristol Myers Squibb Trading Down 0.9%

Shares of NYSE BMY opened at $60.21 on Friday. The company has a current ratio of 1.26, a quick ratio of 1.14 and a debt-to-equity ratio of 2.32. The stock has a market capitalization of $122.62 billion, a PE ratio of 17.45, a PEG ratio of 0.17 and a beta of 0.26. Bristol Myers Squibb Company has a twelve month low of $42.52 and a twelve month high of $63.33. The stock has a fifty day simple moving average of $57.66 and a 200-day simple moving average of $51.01.

Bristol Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.65 by ($0.39). The firm had revenue of $12.50 billion for the quarter, compared to analyst estimates of $12.24 billion. Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.Bristol Myers Squibb’s revenue was up 1.3% on a year-over-year basis. During the same period in the previous year, the company posted $1.67 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, equities analysts forecast that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 1st. Stockholders of record on Thursday, April 2nd will be paid a $0.63 dividend. The ex-dividend date of this dividend is Thursday, April 2nd. This represents a $2.52 annualized dividend and a dividend yield of 4.2%. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 73.04%.

More Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: U.S. FDA approved Sotyktu (deucravacitinib) for adults with active psoriatic arthritis — a label expansion that can broaden Sotyktu’s market opportunity and revenue runway. U.S. FDA Approves Bristol Myers Squibb’s Sotyktu® (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis
• Positive Sentiment: BMY declared a quarterly dividend of $0.63/share (ex-dividend April 2), maintaining a high-yield payout that supports income-focused investors and can underpin the stock’s valuation. Dividend Announcement
• Positive Sentiment: Reblozyl showed positive Phase 2 results in alpha-thalassemia and has exceeded $2.3B in annualized sales — evidence Reblozyl is becoming a material growth driver as older drugs decline. Reblozyl Phase 2 Success Shapes Bristol Myers Squibb Valuation Story
• Neutral Sentiment: Bristol-Myers Squibb is tracking the real-world impact of KarXT in schizophrenia — useful clinical/market data but longer-term and unlikely to move near-term earnings. Bristol-Myers Squibb Tracks Real-World Impact of KarXT in Schizophrenia
• Negative Sentiment: Q4 results showed revenue roughly in line but EPS missed consensus (reported $1.26 vs. ~$1.65 expected), which prompted investor selling and weighed on the stock. Earnings and Market Reaction
• Negative Sentiment: Recent articles highlight a larger-than-market intraday decline and analyst focus on legacy-product pressures — shorter-term sentiment and volatility remain a risk until new product growth scales. Bristol Myers Squibb (BMY) Registers a Bigger Fall Than the Market

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.